Empagliflozin reduces risk of cardiovascular death by 38 pc

The new standard of care in effective diabetes management, Empagliflozin, reduces the risk of cardiovascular death by 38 per cent and hospitalisation for heart failure by 35 per cent in people with high risk type-2 diabetes, a study has said.
The findings of the EMPA-REG OUTCOME suggest a significant reduction in the risk of progressive kidney disease in adults with type-2 diabetes, with established cardiovascular disease CVD. The recently concluded EMPA-REG global trial of more than 7,000 patients from 42 countries, also included close to 163 enrolled from Indian patients with type 2 diabetes and established CVD.
"As per the results of the EMPA-REG Outcome trial, Empagliflozin reduces the risk of cardiovascular death by 38 per cent and hospitalisation for heart failure by 35 per cent in people with high risk type 2 diabetes.

"It also reduces the risk for new-onset or worsening kidney disease by 39 per cent versus placebo when added to standard of care in people with type 2 diabetes with established cardiovascular disease," Mumbai's leading endocrinologist Shashank Joshi told reporters here.
This is the new standard of care in effective diabetes management with a holistic approach towards patient care, Joshi said.
Prevalence of type 2 diabetes mellitus (T2DM) is increasing globally and has reached epidemic proportions in many countries especially India.

Joshi highlighted an increased prevalence of cardiovascular disease (CVD) and kidney disease in people with type 2 diabetes and the need for a paradigm shift in effective diabetes management.

Kidney disease affects about 50 per cent of people with type 2 diabetes whereas people with diabetes are two to four times more likely to develop CVD than people without diabetes due to factors such as such as high blood sugar, high blood pressure and obesity
Joshi said, "Uncontrolled diabetes can lead to serious complications such as CVD, kidney problems or other serious health complications. The risk for cardiovascular events increases in patients with type 2 diabetes as they age. Cardiovascular disease is the leading cause of death in predominant number of patients with type 2 diabetes."
Diabetic patients in the country are often diagnosed late and have huge burden of cardiovascular and renal burden of complications which need effective early screening and treatment strategies.